These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33148948)

  • 1. TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
    Judge PK; Haynes R
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):123-130. PubMed ID: 33148948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neprilysin inhibition in chronic kidney disease.
    Judge P; Haynes R; Landray MJ; Baigent C
    Nephrol Dial Transplant; 2015 May; 30(5):738-43. PubMed ID: 25140014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neprilysin inhibition and chronic kidney disease].
    Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
    G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
    UK HARP-III Collaborative Group
    Nephrol Dial Transplant; 2017 Dec; 32(12):2043-2051. PubMed ID: 27646835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application.
    Kuang H; Huang X; Zhou Z; Cheng X; Xu G
    Eur J Pharmacol; 2021 Sep; 907():174288. PubMed ID: 34216577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis.
    Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J
    Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-neprilysin inhibition in ckd: does it confer a double benefit?].
    Wojtaszek E
    Wiad Lek; 2019; 72(11 cz 2):2228-2231. PubMed ID: 31860842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
    Malek V; Gaikwad AB
    Biomed Pharmacother; 2017 Jun; 90():752-759. PubMed ID: 28419972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.
    Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G
    Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
    von Lueder TG; Sangaralingham SJ; Wang BH; Kompa AR; Atar D; Burnett JC; Krum H
    Circ Heart Fail; 2013 May; 6(3):594-605. PubMed ID: 23694773
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    Díez J
    Eur J Heart Fail; 2017 Feb; 19(2):167-176. PubMed ID: 27766748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney disease, heart failure and neprilysin inhibition.
    Haynes R; Zhu D; Judge PK; Herrington WG; Kalra PA; Baigent C
    Nephrol Dial Transplant; 2020 Apr; 35(4):558-564. PubMed ID: 31028383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.
    Tsukamoto S; Uehara T; Azushima K; Wakui H; Tamura K
    J Am Heart Assoc; 2023 Apr; 12(8):e029565. PubMed ID: 37066800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry).
    Jiménez-Blanco Bravo M; Valle A; Gayán Ordás J; Del Prado Díaz S; Cordero Pereda D; Morillas Climent H; Bascompte Claret R; Seller Moya J; Zamorano Gómez JL; Alonso Salinas GL
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e662-e668. PubMed ID: 34321396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.